KRAS, NRAS, and HRAS are the three main isoforms affected in cancer; among them, KRAS is the most frequent gain-of-function mutation, occurring in up to 90% of pancreatic cancer, 50% of colorectal cancer, and 30% of lung adenocarcinoma (2–6). This evidence concerns the gene KRAS and cancer.